Skip to main content

Moclobemide in social phobia: a controlled dose-response trial.

Publication ,  Journal Article
Noyes, R; Moroz, G; Davidson, JR; Liebowitz, MR; Davidson, A; Siegel, J; Bell, J; Cain, JW; Curlik, SM; Kent, TA; Lydiard, RB; Mallinger, AG ...
Published in: J Clin Psychopharmacol
August 1997

Although the monoamine oxidase inhibitor phenelzine has proven efficacious in social phobia, the risk of hypertensive crises has reduced its acceptability. The reversible monoamine oxidase inhibitor moclobemide has less potential for such reactions, but its efficacy in this disorder remains unproven. A double-blind, placebo-controlled study was undertaken to assess the efficacy and safety of fixed doses of moclobemide. After a 1-week placebo run-in, subjects with social phobia were randomly assigned to placebo or one of five doses (75 mg, 150 mg, 300 mg, 600 mg, or 900 mg daily) of moclobemide for 12 weeks. Although a trend toward greater efficacy of higher doses of moclobemide was observed at 8 weeks, no differences in response to various doses of the drug and placebo were observed at 12 weeks. At 12 weeks, 35% of subjects on 900 mg of moclobemide and 33% of those on placebo were at least much improved. Moclobemide was well tolerated, insomnia being the only dose-related adverse event observed with the drug. In this dose-response trial, moclobemide did not demonstrate efficacy at 12 weeks. Some other controlled studies have found moclobemide and brofaromine, another reversible monoamine oxidase inhibitor, efficacious in social phobia. Possible reasons for inconsistent findings are discussed.

Duke Scholars

Published In

J Clin Psychopharmacol

DOI

ISSN

0271-0749

Publication Date

August 1997

Volume

17

Issue

4

Start / End Page

247 / 254

Location

United States

Related Subject Headings

  • Psychiatry
  • Psychiatric Status Rating Scales
  • Phobic Disorders
  • Monoamine Oxidase Inhibitors
  • Moclobemide
  • Male
  • Humans
  • Female
  • Double-Blind Method
  • Dose-Response Relationship, Drug
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Noyes, R., Moroz, G., Davidson, J. R., Liebowitz, M. R., Davidson, A., Siegel, J., … Uhlenhuth, E. H. (1997). Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol, 17(4), 247–254. https://doi.org/10.1097/00004714-199708000-00002
Noyes, R., G. Moroz, J. R. Davidson, M. R. Liebowitz, A. Davidson, J. Siegel, J. Bell, et al. “Moclobemide in social phobia: a controlled dose-response trial.J Clin Psychopharmacol 17, no. 4 (August 1997): 247–54. https://doi.org/10.1097/00004714-199708000-00002.
Noyes R, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug;17(4):247–54.
Noyes, R., et al. “Moclobemide in social phobia: a controlled dose-response trial.J Clin Psychopharmacol, vol. 17, no. 4, Aug. 1997, pp. 247–54. Pubmed, doi:10.1097/00004714-199708000-00002.
Noyes R, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, Bell J, Cain JW, Curlik SM, Kent TA, Lydiard RB, Mallinger AG, Pollack MH, Rapaport M, Rasmussen SA, Hedges D, Schweizer E, Uhlenhuth EH. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug;17(4):247–254.

Published In

J Clin Psychopharmacol

DOI

ISSN

0271-0749

Publication Date

August 1997

Volume

17

Issue

4

Start / End Page

247 / 254

Location

United States

Related Subject Headings

  • Psychiatry
  • Psychiatric Status Rating Scales
  • Phobic Disorders
  • Monoamine Oxidase Inhibitors
  • Moclobemide
  • Male
  • Humans
  • Female
  • Double-Blind Method
  • Dose-Response Relationship, Drug